PT - JOURNAL ARTICLE AU - Ariel L. Rivas AU - Almira L. Hoogesteijn AU - James B. Hittner AU - Folorunso O. Fasina AU - Marc H.V. van Regenmortel TI - Addressing a complicated problem: can COVID-19 asymptomatic cases be detected – and epidemics stopped− when testing is limited and the location of such cases unknown? AID - 10.1101/2020.11.10.20223495 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.10.20223495 4099 - http://medrxiv.org/content/early/2020/11/13/2020.11.10.20223495.short 4100 - http://medrxiv.org/content/early/2020/11/13/2020.11.10.20223495.full AB - Can the COVID-19 pandemic be stopped when the principal disseminators −asymptomatic cases− are not easily observable? This question was addressed exploring the cumulative epidemiologic data reported by 51 countries, up to October 2, 2020. In particular, the validity of test positivity and its inverse (the ratio of tests performed per case detected) to indicate whether asymptomatic cases are being detected and isolated –even when only a minor percentage of the population is tested− was evaluated. By linking test positivity data to the number of COVID-19 related deaths reported per million inhabitants, the research question was answered: countries that expressed a high percentage of test positivity (>5%) reported, on average, 15 times more deaths than countries that exhibited <1% test positivity. It is suggested that such a large difference in outcomes is due to the exponential growth that epidemics may experience when silent (asymptomatic) cases are not detected and, consequently, the disease disseminates. Because temporal and geo-referenced data on test positivity may facilitate cost-effective, site-specific testing policies, it is postulated that the risk of uncontrolled epidemics may be ameliorated when test positivity is investigated.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational study based on open-sourced dataset.Funding StatementNo funding was obtained for this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was based on open-access datasets. Hence no oversight function was needed by the Institutional oversight committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publically available. https://ourworldindata.org/coronavirus-testing#how-many-tests-are-performed-each-day